AA
CLSD

ALPS Advisors’s Clearside Biomedical CLSD Stock Holding History

ALPS Advisors’s Portfolio CLSD Stock Details CLSD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-3,778
Closed -$349K – 888
2018
Q3 		$349K Buy
3,778
+688
+22% +$81.8K ﹤0.01% 884
2018
Q2 		$496K Buy
+3,090
New +$521K ﹤0.01% 582
2017
Q2 		– Sell
-1,408
Closed -$168K – 774
2017
Q1 		$168K Buy
1,408
+90
+7% +$10.6K ﹤0.01% 712
2016
Q4 		$177K Buy
+1,318
New +$331K ﹤0.01% 699

Other funds holding CLSD

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
NC
Northpointe Capital Bloomfield Hills, Michigan $258M AUM 1.97% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ALPS Advisors's CLSD Position: Q4 2018 in Review

ALPS Advisors sold out of Clearside Biomedical (CLSD) in Q4 2018, closing a stake of 3,778 shares — an estimated $349K sold.

ALPS Advisors first reported a position in CLSD in Q4 2016 and held it in 4 quarters. The position peaked at $496K in Q2 2018. 69 funds tracked by Wall St. Rank hold CLSD as of Q4 2018.

  • ALPS Advisors reported no remaining Clearside Biomedical position as of Q4 2018 after selling out during the quarter.
  • ALPS Advisors sold 3,778 Clearside Biomedical shares in Q4 2018, an estimated $349K.
  • ALPS Advisors first reported a position in Clearside Biomedical in Q4 2016 and held it in 4 quarters.
  • ALPS Advisors's Clearside Biomedical position peaked at $496K in Q2 2018.
  • 69 funds tracked by Wall St. Rank held Clearside Biomedical as of Q4 2018.

Based on ALPS Advisors's 13F filing for Q4 2018, filed 4 Feb 2019.